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Abstract High-dose intravenous immunoglobulin (IVIG)
therapy has been effective in treating various autoimmune
and systemic inﬂammatory diseases. Here, we assessed the
efﬁcacy and safety of IVIG therapy with polyethylene gly-
col-treated human IgG (drug code GB-0998) for patients
with corticosteroid-refractory polymyositis (PM) and der-
matomyositis (DM) by means of a randomized, double-
blind, placebo-controlled study. We randomly assigned 26
subjects (16 PM and 10 DM) to receive either GB-0998
or placebo. Intragroup comparison in the GB-0998
group showed statistically signiﬁcant improvements due to
GB-0998 administration in the primary endpoint (manual
muscle test score) and secondary endpoints (serum creatine
kinase level and activities of daily living score). However,
signiﬁcant improvements were also found in the placebo
group, and comparison of the GB-0998 group with the pla-
cebo group did not show any signiﬁcant difference between
the groups. We discuss possible reasons for the absence of a
clear intergroup difference in efﬁcacy. Nineteen adverse
drugreactionswereobservedin11of26subjects(42.3%),of
which 2 events (decreased muscle strength and increased
serum creatine kinase) were assessed as serious; however,
theyarepreviouslyknownevents.Theseresultsindicatethat
GB-0998 can be safely used with the same precautions as
other current IVIG therapy.
Keywords Intravenous immunoglobulin (IVIG)  Manual
muscle test (MMT)  Polymyositis (PM)  Dermatomyositis
(DM)  Randomized, double-blind, placebo-controlled
study
Introduction
Polymyositis (PM) and dermatomyositis (DM) are diffuse
inﬂammatory myopathies of unknown etiology, causing
decreased strength in the limb proximal group muscles,
cervical muscles, and pharyngeal muscles, and have been
designated as targets for disease treatment research by the
Japanese Ministry of Health, Labor, and Welfare. Oral
corticosteroids are the ﬁrst-line treatment for patients with
PM and DM, and they produce good response in approxi-
mately 80% of patients [1]. For patients showing either no
response or incomplete response, other therapies such as
methylprednisolone pulse therapy and/or concomitant
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are not always effective [2]. In addition, long-term and/
or high-dose administration of corticosteroids and/or
immunosuppressive drugs may cause severe side-effects,
such as infection, and therefore new therapies are
required.
Here, we present the results of a double-blind, placebo-
controlled, crossover study designed to evaluate the efﬁcacy
and safety of polyethylene glycol-treated human IgG (GB-
0998) in patients with corticosteroid-resistant PM or DM.
Patients and methods
Study design
This randomized, double-blind, placebo-controlled, cross-
over trial was performed in 47 medical institutions in
Japan. The study protocol was approved by the Institutional
Review Board of each participating institution, and the
trial was carried out in accordance with the Declaration
of Helsinki and Good Clinical Practice. Patients gave
written informed consent prior to registration for this study.
This trial is registered with ClinicalTrials.gov, number
NCT00335985.
The trial began with a 6-week run-in period, during
which corticosteroid resistance was conﬁrmed. Patients
who had given informed consent, and had been conﬁrmed
to be resistant to corticosteroid treatment during the run-in
period, were randomly allocated to receive GB-0998
(Benesis Corporation, Osaka, Japan), a polyethylene gly-
col-treated human normal immunoglobulin, followed by an
indistinguishable placebo (GB-0998 group), or the same
two treatments in the reverse order (placebo group), as
shown in Fig. 1. GB-0998 at a dose of 400 mg (8 mL)/kg/
day or the placebo was administered by intravenous infu-
sion once daily for 5 consecutive days, in a double-blind
manner. After an assessment duration of 8 weeks from the
start of administration (the ﬁrst period), subjects receiving
the active drug were switched to receive the placebo in the
second period, whereas those receiving the placebo in
the ﬁrst period were switched to receive the active drug in
the second period. The assessment duration in the second
period was 8 weeks, and there was an additional 4-week
observation period (follow-up period) after the second
period. Because of the seriousness of the disease, the sec-
ond period was included in the study design to enable all
subjects in the study to receive GB-0998. For ethical rea-
sons, patients who did not show disease alleviation within
4 weeks after the start of the ﬁrst period, rendering con-
tinuation of the study difﬁcult, were given an early tran-
sition to the second period; i.e., these subjects were
transferred to the second period without continuing in the
ﬁrst period for the full 8 weeks. For this reason, the pri-
mary evaluation was of efﬁcacy in the ﬁrst period.
Increases in corticosteroid and immunosuppressant
doses, including methylprednisolone pulse therapy, were
not allowed during the period from acquisition of informed
consent until completion or termination of the study.
Decreases in the dose were allowed when side-effects were
elicited by corticosteroid or immunosuppressant during the
period prior to the start of test drug administration, and
were also allowed depending on the patients’ medical
condition following the administration of the test drug.
Patients
Patients with corticosteroid-resistant PM/DM (Japanese
people, resident in Japan) who were aged 16–75 years and
fulﬁlled the diagnostic criteria of Bohan and Peter [3] for
‘‘deﬁnite’’ PM/DM were considered eligible to participate
in this study. Among them, those that met one of the
following criteria with respect to their history of cortico-
steroid therapy were enrolled for this study after obtaining
their informed consent:
1. Had received high-dose corticosteroid therapy
(C50 mg/day or C1 mg/kg/day for 1 month or more),
startingbetween6 weeksand1 yearpriortoacquisition
of informed consent, and continued until the day of
acquisition of informed consent.
2. In receipt of C50 mg/day or C1 mg/kg/day of cortico-
steroids on the day of acquisition of informed consent.
3. Had received two or more methylprednisolone
pulse therapies within 6 weeks before the acquisition
of informed consent, and receiving C30 mg/day or
C0.6 mg/kg/day of corticosteroid on the day of
acquisition of informed consent.
Patients with manual muscle test (MMT) scores of B80
points (normal score 90 points), assessed after having
obtained their informed consent, and with twice the stan-
dard upper limit value of serum creatine kinase (CK) or
more were tentatively enrolled, and followed for 6 weeks
(run-in period). The patients who did not show any
Fig. 1 Outline of study design. GB-0998 (active drug) was admin-
istered to the GB-0998 group in the ﬁrst period and to the placebo
group in the second period. Differences between before and after the
8-week ﬁrst period in the GB-0998 group were assessed in the
primary analysis
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these 6 weeks were formally registered, and received the
investigational drug.
Patients excluded from participation in this study were
those with malignant tumors; acute interstitial pneumonia
including acute exacerbation of chronic phase; severe mus-
cular atrophy for a long period; severe infectious disease;
severehepaticdisorderorsevererenaldisorder;thosewhohad
aprevioushistoryofshockorhypersensitivitytothetestdrug;
those who had a history of cerebral infarction or ischemic
heart disease, or had symptom of these diseases; those who
hadahistoryofIgAdeﬁciencydiagnosed;pregnant,lactating,
and possibly pregnant patients; patients who wanted to
become pregnant; and those who had been administered
immunoglobulin within 6 weeks of obtaining consent.
Efﬁcacy assessment
Since muscle weakness is the most common symptom of
PM/DM, changes in MMT scores were used as the primary
endpoint, because the therapeutic effect could be assessed
by observing the degree to which muscular strength was
restored. MMT was scored on the following 18 muscles:
the right and left of each of the following: deltoid, biceps
brachii, brachioradialis, triceps brachii, iliopsoas, gluteus
maximus, quadriceps femoris, and hamstring muscle; and
the ﬂexor and extensor muscles of the neck area. Each
muscle was scored 0–5, with a healthy state thus being a
score of 90 [4, 5]. In order to achieve consistency of
evaluation, in principle, a single assessor evaluated the
MMT for all patients throughout the study.
The secondary efﬁcacy endpoints were serum CK level
and the activities of daily living (ADL) score. Serum CK
measurements and other clinical laboratory tests were
carried out at a central laboratory, at Mitsubishi Chemical
Medience Corporation (Tokyo, Japan). The upper limits of
the normal serum CK range were taken as 270 and 150 IU/
L for males and females, respectively. The ADL score was
based on the following 15 actions, with each action being
scored 0–3, and the normal total score being 45: raising
arms, taking off outer clothes, turning on water tap,
combing hair, fastening buttons, getting out of bed, lifting
up feet, standing up from chair, climbing stairs, walking on
ﬂat surface, turning over in bed, holding up head, sitting
down on bed, having conversation, and swallowing [4, 5].
In addition to the above endpoints, we considered the
time (number of days) to discharge from hospital during
the ﬁrst period. Furthermore, two additional parameters
evaluated were dysphagia, which was graded as none, mild,
or severe by each attending physician, and the occurrence
or nonoccurrence of early transition to the second period.
The safety endpoint was the occurrence or nonoccur-
rence of adverse events.
Target number of subjects
The number of patients meeting the criteria for inclusion in
this study is very small. It was therefore considered that,
with a study duration of 3 years, the number of subjects
who could be enrolled would be limited to 20. Therefore,
from the viewpoint of the feasibility of carrying out the
study, the target number of subjects was set at 10 per group
(a total of 20 subjects).
Statistical analysis
As described above, the number of target patients for this
studywasverysmall,anditwasnotpracticallypossibletoset
the target number of subjects sufﬁciently high to permit a
clear demonstration of the superiority of GB-0998 over
placebo. Therefore, the primary analysis consisted of an in-
tragroupcomparison inthe GB-0998group,usingthe paired
t test, of changes in MMT score, serum CK level, and ADL
score between before initiation of study drug administration
and after administration for 8 weeks in the ﬁrst period.
An intergroup comparison between the GB-0998 and
placebo groups was also carried out as a subsidiary anal-
ysis. For this analysis, descriptive statistics were calculated
separately for the two groups, with respect to the changes
in MMT score, serum CK level, and ADL score between
before initiation of administration during the ﬁrst period
and after administration for 8 weeks. The serum CK levels
were widely scattered, depending upon the severity of
disease in each subject, and logarithmic transformation was
therefore carried out for efﬁcacy evaluation in relation to
change in serum CK level. Then, using the mean changes
in these parameters, the point-estimation value and 95%
conﬁdence interval were calculated for the difference
between the GB-0998 and placebo groups.
In addition, the Kaplan–Meier method was used to
compare the time (number of days) until improvement of
the MMT score in the GB-0998 and placebo groups. On the
basis of a report by Dalakas et al. [6], the time at which
‘‘improvement’’ was taken to have occurred was the ﬁrst
time point when the MMT score was increased by 5 or
more (and subsequently maintained at the higher level)
during the period from before initiation of administration
during the ﬁrst period until transition to the second period.
The median value of the time was calculated for each
group, and the log-rank test was applied.
For the serum CK level, the Kaplan–Meier method was
used to compare the time (number of days) until normali-
zation in the GB-0998 and placebo groups. The event taken
to constitute ‘‘normalization’’ was the serum CK reaching a
level below the upper limit of the normal range for the ﬁrst
time during the period from before initiation of adminis-
tration during the ﬁrst period until transition to the second
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and the generalized Wilcoxon test was applied.
With respect to parameters other than the primary and
secondary endpoints, the Kaplan–Meier method was used
to compare the time (number of days) until ﬁrst discharge
from hospital during the ﬁrst period. The median value was
calculated for each of the groups.
Several supplementary analyses were also carried out, as
follows. For MMT score, the percentage of subjects
showing improvement was calculated for each group. In
addition, for each of the individual muscles evaluated, an
intergroup comparison using the paired t test was carried
out for the change during the ﬁrst period. For ADL score,
the paired t test was used for intergroup comparison of the
change in each evaluated individual action during the ﬁrst
period. In addition, the change in dysphagia during the ﬁrst
period was calculated, and the Fisher direct probability test
was used for intergroup comparison of the elimination or
nonelimination of dysphagia. Numbers of subjects under-
going early transition to the second period were also
compared in the two groups.
Efﬁcacy was assessed using the last observation carried
forward (LOCF) approach at 8 weeks after the start of
administration in the ﬁrst period, when premature discon-
tinuation occurred in the ﬁrst 8-week period, or when the
second period was started before the scheduled end of the
ﬁrst period. Similarly, when premature discontinuation
occurred in the second 8-week period, the efﬁcacy after
8 weeks for the second period was assessed using the
LOCF approach.
Results
Background of subjects
Of 63 subjects who gave informed consent to participate in
the study, corticosteroid resistance was conﬁrmed in 26 (12
in the GB-0998 group and 14 in the placebo group). Study
drug administration and evaluation of safety and efﬁcacy
were carried out with these subjects (Fig. 2).
Table 1 presents the backgrounds of these subjects,
separately for each of the two groups. In the GB-0998 group
there were 6 subjects with PM and 6 with DM, while in the
placebo group, there were 10 with PM and 4 with DM.
Results of principal analyses: intragroup comparison
during the ﬁrst period
With respect to the principal analyses of the primary and
secondary endpoints, Table 2 presents the changes in efﬁ-
cacy endpoints between before initiation of study drug
administration, and after administration for 8 weeks during
the ﬁrst period.
The MMT score was the primary endpoint, and the
mean (±standard deviation, SD) of the change in this score
in the GB-0998 group during the ﬁrst period was
11.8 ± 8.0, this change being statistically signiﬁcant
according to the paired t test (p = 0.0004). In terms of
classiﬁcation by disease type, the mean scores in subjects
with PM and DM were 12.2 ± 11.0 and 11.3 ± 4.5,
respectively; thus, no marked difference was found
between PM and DM subjects.
Serum CK level and the ADL score were the secondary
endpoints. The mean (±SD) of the change in serum CK
level was -1.1633 ± 1.4123 Ln (IU/L) (paired t test,
p = 0.0157), and the mean (±SD) of the change in the
ADL score was 7.3 ± 6.6 (paired t test, p = 0.0029). The
changes in both these parameters were statistically
signiﬁcant.
Statistically signiﬁcant increases during the ﬁrst period
were also found in the intragroup comparison in the
placebo group. The mean change in MMT score was
9.9 ± 8.3 (paired t test, p = 0.0007), the mean change in
serum CK level was -1.2662 ± 0.8900 Ln (IU/L) (paired
t test, p = 0.0001), and the mean change in ADL score was
4.0 ± 5.8 (paired t test, p = 0.0237).
Results of subsidiary analyses: intergroup analyses
Changes during the ﬁrst period
The results for intergroup comparison of MMT score,
serum CK level, and ADL score during the ﬁrst period are
presented in Table 2.
Fig. 2 Flow diagram of patients participating in this trial. In this
study, a total of 26 subjects received GB-0998. Asterisk Premature
discontinuation occurred after the sixth week of the ﬁrst period
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123Table 1 Patients’ characteristics
Characteristic GB-0998 group (n = 12) Placebo group (n = 14) Total (n = 26)
Gender, n (%)
Male 1 (8.3) 5 (35.7) 6 (23.1)
Female 11 (91.7) 9 (64.3) 20 (76.9)
Age (years)
Mean 50.6 48.1 49.3
Standard deviation 13.1 12.1 12.4
Minimum value 27 30 27
Median 49.0 50.5 49.0
Maximum value 69 68 69
Diagnosis, cases (%)
Polymyositis 6 (50.0) 10 (71.4) 16 (61.5)
Dermatomyositis 6 (50.0) 4 (28.6) 10 (38.5)
Disease period, cases (%)
\6 months 5 (41.7) 3 (21.4) 8 (30.8)
C6 months and\1 year 0 (0.0) 4 (28.6) 4 (15.4)
C1 year 7 (58.3) 7 (50.0) 14 (53.8)
Interstitial pulmonary disease, cases (%)
Absence 6 (50.0) 11 (78.6) 17 (65.4)
Presence 6 (50.0) 3 (21.4) 9 (34.6)
Daily dose of corticosteroid at formal registration (mg)
Mean 34.79 40.71 37.98
Standard deviation 14.56 14.69 14.65
Minimum value 10 7.5 7.5
Median 35.00 47.50 42.50
Maximum value 60 55 60
Therapeutic history with immunosuppressant, cases (%)
Absence 5 (41.7) 7 (50.0) 12 (46.2)
Presence 7 (58.3) 7 (50.0) 14 (53.8)
Manual muscle test score at formal registration (points)
0–50 2 1 3
51–60 4 3 7
61–70 4 8 12
71–80 2 2 4
Mean ± SD 61.8 ± 10.6 64.7 ± 9.0 –
Minimum value 42 43 42
Maximum value 77 77 77
Activities of daily living score at formal registration (points)
0–15 3 2 5
16–20 3 1 4
21–25 0 1 1
26–30 2 0 2
31–35 2 5 7
36–40 2 3 5
41–45 0 2 2
Not done 0 0 0
Mean ± SD (points) 23.8 ± 11.1 30.2 ± 10.3 –
Minimum value 4 11 4
Maximum value 40 45 45
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mean MMT scores during the ﬁrst period was 1.9, with the
95% conﬁdence interval being -4.8 to 8.5. As for the
secondary endpoints, the difference between the mean
logarithmic serum CK levels was 0.1029 Ln (IU/L), with
the 95% conﬁdence interval being -0.8382 to 1.0439, and
the mean difference between the ADL scores was 3.3, with
the 95% conﬁdence interval being -1.8 to 8.3. The
GB-0998 group showed numerically greater changes in the
MMT and ADL scores than did the placebo group, but
the differences were not statistically signiﬁcant. In addi-
tion, the placebo group showed a greater change of serum
CK level than did the GB-0998 group, but this difference
was not statistically signiﬁcant.
Time to improvement in MMT score
The time (number of days) until the improvement in the
MMT score reached 5 or more was compared between the
two groups.
The Kaplan–Meier survival curves for the time until
improvement are shown in Fig. 3. The median times until
improvement were 16.5 days in the GB-0998 group, and
29.0 days in the placebo group, but the difference between
the two groups was not statistically signiﬁcant (log-rank
test, p = 0.1154).
Time until normalization of serum CK level
The Kaplan–Meier survival curves for time (number of
days) until the ﬁrst normalization of serum CK level after
initiation of study drug administration during the ﬁrst
period are shown in Fig. 4. The median time until nor-
malization of the serum CK level was signiﬁcantly less in
the GB-0998 group, at 22.0 days, than in the placebo
group, in which it was 57.5 days (generalized Wilcoxon
test, p = 0.0301).
Time until discharge from hospital
The time until the ﬁrst discharge from hospital after initi-
ation of administration during the ﬁrst period was analyzed
using the Kaplan–Meier method, as shown in Fig. 5. The
median time (number of days) until discharge was
11.5 days in the GB-0998 group, and 41.5 days in the
placebo group. In the GB-0998 group, all 12 subjects were
discharged from hospital during the ﬁrst period, whereas
Table 2 Differences of assessment parameters between before administration and at 8 weeks after start of administration for the ﬁrst phase and
corresponding between-group differences
No. of
subjects
Mean Standard
deviation
Minimum
value
Median Maximum
value
Corresponding
t test
Difference of mean (GB-0998
group - placebo group)
95% conﬁdence interval
MMT
GB-0998 12 11.8 8.0 -4 11.0 25 t = 5.0655
p = 0.0004
1.9 (-4.8 to 8.5)
Placebo 14 9.9 8.3 0 8.0 22 t = 4.4334
p = 0.0007
CK
GB-0998 12 -1.1633 1.4123 -3.006 -1.4389 1.229 t =- 2.8533
p = 0.0157
0.1029 (-0.8382 to 1.0439)
Placebo 14 -1.2662 0.8900 -2.797 -1.4353 -0.134 t =- 5.3229
p = 0.0001
ADL
GB-0998 12 7.3 6.6 -1 6.0 26 t = 3.8169
p = 0.0029
3.3 (-1.8 to 8.3)
Placebo 14 4.0 5.8 -4 3.0 18 t = 2.5610
p = 0.0237
The primary before–after analysis was performed using t tests to evaluate the differences in MMT scores, serum CK levels, and ADL scores
between before the administration of the drug and at 8 weeks after the start of the administration in the ﬁrst phase. As a subanalysis, descriptive
statistics were calculated by group and the before–after differences (between before the drug administration and at 8 weeks after the start of the
administration in the ﬁrst phase) were compared for each assessment parameter. The between-group differences (GB-0998 group versus placebo
group) and conﬁdence intervals for means of differences between before and after administration were estimated based on analysis of variance.
Patients whose treatment was discontinued or who were transferred to the second phase before 8 weeks after the start of administration in the ﬁrst
phase were assessed after 8 weeks in the ﬁrst phase using the LOCF approach
MMT manual muscle test, CK creatine kinase, ADL activities of daily living
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123only 8 of 14 subjects in the placebo group were discharged
during the ﬁrst period.
Results of supplementary analyses and investigations
Percentage of subjects showing improvements in MMT
score
The time-courses of percentage of subjects showing
improvement in MMT score are shown in Fig. 6a. Even
after week 8 of the ﬁrst period, no statistically signiﬁcant
intergroup difference in the percentage of subjects showing
improvement was found (Fisher direct probability test,
p = 0.0809). However, in the GB-0998 group the per-
centage showing improvement at week 8 was 91.7% (11 of
12 subjects); further, the percentage showing improvement
increased up to week 6, and was then maintained even after
the week-8 time-point. In the placebo group, on the other
hand, the percentage showing improvement at week 8 was
57.1% (8 of 14 subjects), this percentage having shown no
increase from week 4. In addition, at week 8 of the second
period, the percentage of the GB-0998 group (administered
placebo during the second period) that showed improve-
ment was 81.8% (9 of 11 subjects), and the percentage of
the placebo group (administered GB-0998 during the
second period) that showed improvement was 84.6% (11 of
13 subjects). In the GB-0998 group, the percentage that
showed improvement at week 8 of the second period was
approximately the same as that at week 8 of the ﬁrst
period. However, in the placebo group the percentage that
showed improvement increased during the second period,
when they were receiving GB-0998, and became approxi-
mately the same as the percentage in the GB-0998 group
during the ﬁrst period (when they were receiving GB-0998)
(Fig. 6b).
We found that 42.9% (6 of 14 subjects) of the placebo
group had no improvement in MMT score during the ﬁrst
period. These subjects did not show improved muscle
strength at the initiation of the second period, despite
having undergone corticosteroid therapy by that time, but
four of them did show improvements in MMT score with
GB-0998 administration during the second period.
MMT scores classiﬁed by evaluated muscle
The intergroup differences in changes of individual MMT
scores in the 18 muscles evaluated in this study, during the
ﬁrst period, are shown in Fig. 7. The point-estimation
values were greater in the GB-0998 group than in the
placebo group for 14 of the 18 muscles, although the
differences were small for all individual muscles.
ADL scores classiﬁed by evaluated parameter
The intergroup differences in changes of ADL scores for
the 15 actions evaluated in this study, during the ﬁrst
Fig. 3 Kaplan–Meier curve of patients for whom the MMT scores
increased by 5 points or more in the ﬁrst period. Event occurrence was
deﬁned as the time point when MMT scores initially increased by 5
points or more, and subsequently remained at the higher level, during
the period from before drug administration until transfer to the second
period. When the score was increased by less than 5 points upon
transfer to the second period, the test was discontinued on day 56
Fig. 4 Kaplan–Meier curve of patients in whom serum CK level was
normalized in the ﬁrst period. Event occurrence was deﬁned as the
ﬁrst decline of the serum CK level to below the upper limit of the
normal range during the ﬁrst phase. In one subject whose serum CK
level was not normalized on day 57, the test was discontinued on
day 58
Fig. 5 Kaplan–Meier curve of patients discharged from hospital in
the ﬁrst period. Event occurrence was deﬁned as the ﬁrst discharge
from hospital after test drug administration in the ﬁrst period
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123period, are shown in Fig. 8. The point-estimation values
show that the changes were greater in the GB-0998 group
than in the placebo group for 12 of the 15 actions, although
the differences for individual actions were small. Among
these actions, the difference (value 1.17) with respect to
swallowing action at week 8 of the ﬁrst period between an
increase of 1.00 in the GB-0998 group and a decrease of
-0.17 in the placebo group (the normal score is 3) was
statistically signiﬁcant (t test, p = 0.0222).
Dysphagia
The number of subjects showing symptoms of dysphagia in
the GB-0998 group before initiation of study drug admin-
istration in the ﬁrst period was 7 of 12, whereas the number
in the placebo group was 2 of 14. At week 8 of the ﬁrst
period, the symptoms had ceased in 5 of the 7 subjects in
the GB-0998 group, whereas they had not ceased with
either of the two subjects in the placebo group (Fisher
direct probability test, p = 0.1667).
Transition to the second period
From week 4 of the ﬁrst period, it was permissible to make
an early transition to the second period if alleviation of the
disease was not seen on the basis of the time-courses of
MMT score and serum CK level, if continuation of the ﬁrst
period was judged to be inappropriate, or if it was con-
sidered that treatment intensiﬁcation would have been
necessary. The numbers of subjects experiencing such
early period transitions were 1 of 12 in the GB-0998 group
and 4 of 14 in the placebo group.
Time-courses of MMT scores and serum CK levels
of individual patients for 8 weeks from initial
administration
The time-courses of MMT scores and serum CK levels in
individual patients for 8 weeks after the initial adminis-
tration are shown in Figs. 9, 10, respectively, for both the
GB-0998 and placebo groups. The broken lines indicate the
Fig. 6 a Time-dependent changes in the rate of improved MMT
scores in the ﬁrst period. When MTT score increased by 5 points or
more compared with that before administration of the drug, this was
deﬁned as an improvement. The time-dependent changes in the rate of
improvement are shown by group. For cases discontinued or
transferred to the second period before 8 weeks after the start
of administration in the ﬁrst period, the assessment in each assessment
period was performed using the LOCF approach. Fisher’s exact test
was used to compare the rates of improved MMT scores between the
two groups at the end of the ﬁrst 8-week period. b An MTT score that
increased by 5 points or more compared with before drug adminis-
tration in the ﬁrst period was considered as an improvement, and
improvement rates after 8 weeks in the ﬁrst period and after 8 weeks
in the second period were compared by group. For subjects
discontinued or transferred to the second period before the end of
the 8-week ﬁrst period, the assessment after the ﬁrst period was
performed using the LOCF approach. For subjects discontinued
before the end of the 8-week second period, the assessment after the
second period was performed using the same method
Fig. 7 Forest plots of before–after differences in MMT scores for the
8-week ﬁrst period. Black circles and lines, respectively, represent
point estimates and 95% conﬁdence intervals of between-group
differences (GB-0998 group versus placebo group) concerning MMT
scores for each assessed muscle
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123time-courses in patients after early transition to the second
period.
Safety
Total numbers of adverse events occurring after initiation
of GB-0998 administration were obtained for the 26 sub-
jects receiving the study drug. One hundred one adverse
events occurred in 23 of 26 subjects (88.5%) after initiation
of the ﬁrst period. This total does not include 91 cases of
abnormal changes in clinical laboratory test results that
occurred in 18 subjects. In terms of classiﬁcation by
severity, 89 adverse events in 15 subjects were mild, 11
events in 7 subjects were moderate, and 1 event in 1 subject
was severe. The severe adverse event was cerebral
infarction, but it was considered that there was no causal
relationship between this and GB-0998 administration.
Nineteen adverse drug reactions occurred in 11 of 26
subjects (42.3%). These included gingivitis, hyperkalemia,
disorders of glucose tolerance, diarrhea, dry skin, perspi-
ration disorder, oral herpes, eructation, nausea, increased
serum CK, decreased muscle strength, hot sensation, pur-
pura, chest pain, headache, increased serum b-D-glucan,
increased blood pressure, bronchitis, and fatigue. All these
adverse drug reactions were mild to moderate in severity,
and none occurred more than once.
Four serious adverse events occurred in 3 subjects. Of
these, one case of cerebral infarction in a 36-year-old
female occurred during the ﬁrst period in the GB-0998
group, 50 days after initiation of ﬁrst-period administra-
tion, and continued for 6 days until recovery. This event
was thought to have been due to long-term corticosteroid
administration, and a causal relationship to GB-0998
administration was considered unlikely. A second serious
adverse event, Prinzmetal’s angina in a 56-year-old male,
occurred during the second period, 55 days after initiation
of second-period administration, and continued for 84 days
until improvement. This patient was in the placebo group,
and a considerable time had elapsed since completion of
study drug administration, so a causal relationship with
GB-0998 was considered unlikely. In addition, two adverse
drug reactions in one 47-year-old female in the GB-0998
group occurred during the second period, 56 days after
initiation of ﬁrst-period administration. They were
decreased muscle strength and increased serum CK level,
which continued for 149 days until recovery. A causal
relationship between these events and GB-0998 was judged
to be probable.
These are all known adverse events.
Discussion
Since the ﬁrst report of the use of immunoglobulin for-
mulations to treat PM by Roifman et al. in 1987 [7],
numerous clinical studies have conﬁrmed the efﬁcacy of
intravenous immunoglobulin for treating PM, DM, and/or
juvenile DM resistant to existing treatments. In addition,
various textbooks [8] and guidelines [9, 10] present
immunoglobulin formulations as treatment options for
treatment-resistant PM and DM. However, the only pub-
lished report of a placebo-controlled study relates to a
double-blind, crossover study carried out by Dalakas et al.
in 1993 [6]. Furthermore, the target disease for that study
was treatment-resistant DM, and PM subjects were
excluded.
The present authors have previously carried out two
clinical studies on the use of GB-0998 to treat corticoste-
roid-resistant multiple PM and DM. As in the present
study, the efﬁcacy endpoints in the previous studies were
MMT score, ADL score, and serum CK level, and in those
studies, GB-0998 was found to be effective against corti-
costeroid-resistant multiple PM and DM [4, 5].
However, both of the previous studies were uncon-
trolled, and therefore the present study was designed as a
placebo-controlled, double-blind trial in order to obtain a
more objective efﬁcacy evaluation. In addition, the proto-
col for the present study was made stricter, in that the
criteria for resistance to corticosteroid treatment were more
clearly deﬁned, including an increase of the prestudy run-in
period for conﬁrmation of resistance to 6 weeks from the
4 weeks used in the two previous studies.
Fig. 8 Forest plots of before–after differences in ADL scores for the
8-week ﬁrst period. Black circles and lines, respectively, represent
point estimates and 95% conﬁdence intervals of between-group
differences (GB-0998 group versus placebo group) in the ADL scores
for each activity
390 Mod Rheumatol (2012) 22:382–393
123With respect to the intragroup comparison in the
GB-0998 group, which was the principal analysis, we found
statistically signiﬁcant improvements due to GB-0998
administrationintheprimaryendpoint(MMTscore)andthe
secondary endpoints (ADL score and serum CK level).
Further, the GB-0998 group was statistically signiﬁcantly
superior to the placebo group with respect to the time to
normalization of serum CK level and score of swallowing
action. These results suggest that early normalization of
serum CK level, which is an index of inﬂammation and
increases during the active stage of PM or DM, can be
achieved by administration of GB-0998. Normalization of
serumCKisimportantforachievingimprovementinmuscle
strength, which is the ultimate goal of treatment.
In addition, dysphagia, which is related to swallowing,
occurs in an active and advanced stage of PM and DM, and
is often refractory to corticosteroid treatment; this may
result in aspiration pneumonia, which signiﬁcantly affects
the prognosis [11–13]. It is therefore noteworthy that
GB-0998 also appeared to improve dysphagia, a life-
threatening complication of PM and DM.
With respect to safety, no severe adverse drug reactions
occurred, and all serious adverse drug reactions were
previously known effects. It is therefore considered that
GB-0998 can be administered safely, with the same pre-
cautions that are applied in current IVIG treatments.
However, a case of cerebral infarction did occur in the
present study, although a causal relationship with admin-
istration of the study drug was considered unlikely. In
addition, asymptomatic myocardial infarction was found as
an adverse event in a previous study by the authors [4].
Furthermore, there have been reports of cerebrovascular
and cardiovascular disorders, thought to be due to circu-
latory disturbances associated with increased blood vis-
cosity, when high doses of immunoglobulins were
administered to patients at risk of cerebrovascular and
cardiovascular events [14, 15]. In the treatment of patients
who have, or have a history of, cardiovascular and/or
Fig. 9 Time-courses of MMT
scores of individual subjects for
8 weeks after initiation of ﬁrst-
period administration (a GB-
0998 group, b placebo group).
Broken lines indicate the time-
courses after transfer to the
second period in the cases of
subjects who were transferred
before the full 8 weeks in the
ﬁrst period
Fig. 10 Time-courses of serum
CK levels of individual subjects
for 8 weeks after initiation of
ﬁrst-period administration
(a GB-0998 group, b placebo
group). Broken lines indicate
the time-courses after transfer to
the second period in the cases of
subjects who were transferred
before the full 8 weeks in the
ﬁrst period
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123cerebrovascular disorders, and patients who are at high risk
of developing thromboembolism, careful consideration
should be given before administration of GB-0998, and
careful monitoring is needed after administration.
Thus, the safety and efﬁcacy results in the present study
indicate that GB-0998 has the potential to be a useful drug
for treatment of PM and DM subjects in whom cortico-
steroid treatment has not been effective.
However, the intragroup comparison in the placebo
group also revealed signiﬁcant improvements, and inter-
group comparison of the changes in efﬁcacy endpoints
between before initiation of study drug administration and
after administration for 8 weeks during the ﬁrst period did
not show a signiﬁcant difference between the groups. In
order to clarify the reasons for this, we tried to identify
features of the subjects’ backgrounds that might have led to
signiﬁcant improvement being achieved even with placebo
administration. The results suggested that the inequality of
changes in MMT scores during the prestudy run-in period
may have been the factor that had the most effect on
intergroup difference.
The number of subjects whose MMT scores increased
by 1 or more during the prestudy run-in period was 7 of 26
in the two groups (26.9%). However, a breakdown of these
subjects showed that they consisted of 1 of 12 subjects in
the GB-0998 group, and 6 of 14 in the placebo group, so
subjects who were already showing a tendency toward
recovery thus tended to be more numerous in the placebo
group. When these 7 subjects were excluded, an intergroup
comparison of MMT scores during the ﬁrst period among
the other 19 subjects, who underwent either no change or
deterioration during the prestudy run-in period, gave an
increased intergroup difference, 3.8, with a 95% conﬁdence
interval of -4.4 to 11.9, although this is still not statisti-
cally signiﬁcant. A detailed assessment of the above seven
subjects indicated that they can be considered as subjects in
whom corticosteroid treatment showed some, albeit minor,
efﬁcacy, and therefore it is conceivable there might have
been a carry-over effect from the corticosteroid treatment
in these subjects.
In addition to steroid carry-over effect, the possibility of
steroid myopathy must be considered. The patients in the
present study had been administered steroids at high doses
and/or for extended periods, and steroid administration was
continued during the study period. Therefore, development
of steroid myopathy is a potential issue [8], and one patient
did in fact develop this condition. However, because it is
difﬁcult to distinguish muscle weakness due to steroid
myopathy and that due to the primary disease, PM or DM,
no evaluation of steroid myopathy was carried out in this
study. Therefore, the possibility that evaluation of the
primary endpoint, MMT score, was biased by the effect of
steroid myopathy cannot be ruled out.
Perhaps the greatest limitation of the present study is the
small number of patients included, and it is considered that
the resulting intergroup bias in inclusion of subjects had a
major impact on evaluation of intergroup difference. This
highlights the need for great care in subject allocation to
eliminateintergroupbiasinfuturestudies.However,PMand
DM are rare diseases, and clinical studies with extremely
limited numbers of patients are inevitably problematic.
GB-0998wasapprovedlastyearforcoverbytheJapanese
National Health Insurance system for the indication of
decreasedmusclestrengthduetocorticosteroid-resistantPM
or DM. However, in the light of the present results, we
suggest it would be desirable to carry out a postmarketing
study with all patients administered GB-0998, in order to
obtainclearevidenceastoitsefﬁcacy.Itwillbenecessaryto
evaluatethe efﬁcacyin accordancewith the methodsusedin
clinical studies, in order to assure comparability with the
clinical study results. We think that such continuing evalu-
ation will be important to fully characterize the efﬁcacy of
this drug in corticosteroid-resistant PM and DM, and also to
ensure that the beneﬁt for patients can be maximized.
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